United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $1,153,620.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $320.45, for a total value of $1,153,620.00. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $41,658.50. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $311.04 on Friday. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $325.00. The stock’s fifty day moving average is $281.11 and its two-hundred day moving average is $245.82. The company has a market capitalization of $13.80 billion, a P/E ratio of 14.71, a P/E/G ratio of 1.39 and a beta of 0.55. The company has a quick ratio of 3.64, a current ratio of 3.77 and a debt-to-equity ratio of 0.04.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.63 by $0.54. The firm had revenue of $677.70 million for the quarter, compared to analyst estimates of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. United Therapeutics’s revenue was up 33.7% on a year-over-year basis. During the same period in the previous year, the firm earned $4.86 EPS. Equities analysts expect that United Therapeutics Co. will post 24.73 EPS for the current year.

Analysts Set New Price Targets

UTHR has been the subject of several research reports. Oppenheimer boosted their price target on United Therapeutics from $375.00 to $400.00 and gave the stock an “outperform” rating in a research report on Thursday, May 2nd. HC Wainwright reiterated a “buy” rating and issued a $300.00 target price on shares of United Therapeutics in a research report on Thursday, May 2nd. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 20th. JPMorgan Chase & Co. upped their price objective on shares of United Therapeutics from $280.00 to $300.00 and gave the company an “overweight” rating in a research note on Tuesday, May 21st. Finally, Wells Fargo & Company raised their target price on shares of United Therapeutics from $325.00 to $350.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 12th. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $312.22.

Institutional Trading of United Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. International Assets Investment Management LLC boosted its holdings in United Therapeutics by 13,769.2% during the 4th quarter. International Assets Investment Management LLC now owns 9,015 shares of the biotechnology company’s stock valued at $1,982,000 after acquiring an additional 8,950 shares during the period. DekaBank Deutsche Girozentrale increased its stake in shares of United Therapeutics by 54.4% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 94,643 shares of the biotechnology company’s stock worth $20,617,000 after buying an additional 33,338 shares during the period. Nordea Investment Management AB raised its holdings in shares of United Therapeutics by 155.2% in the 4th quarter. Nordea Investment Management AB now owns 38,698 shares of the biotechnology company’s stock valued at $8,427,000 after purchasing an additional 23,532 shares in the last quarter. BNP Paribas Financial Markets raised its stake in United Therapeutics by 90.3% in the fourth quarter. BNP Paribas Financial Markets now owns 55,481 shares of the biotechnology company’s stock valued at $12,200,000 after buying an additional 26,325 shares in the last quarter. Finally, Duality Advisers LP raised its holdings in United Therapeutics by 56.1% during the fourth quarter. Duality Advisers LP now owns 15,642 shares of the biotechnology company’s stock worth $3,440,000 after purchasing an additional 5,622 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.